Ash 2022 preview – a new multiple myeloma mechanism makes a splash
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
Ash 2022 preview – Affimed and Aptose score
In oncology settings outside multiple myeloma investors have picked two early winners.
ESGCT 2022 – Sangamo strengthens its case in Fabry
The group looks like the gene therapy contender to beat, but that is not saying much.
SITC 2022 preview – cytokines and oral checkpoints
Recently unveiled abstract titles for next month's SITC conference reveal new competition for Incyte’s small-molecule PD-L1 inhibitors.
EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.
TCT 2022 – Otsuka’s renal denervation system shines
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
